EACPT announces Clinical Therapeutics as its new Official Journal

The European Association of Clinical Pharmacology and Therapeutics is delighted to be announce Clinical Therapeutics as its Official Journal, in partnership with the major international publisher Elsevier. 

This interaction is timely both in view of the increasing need to meet international therapeutic challenges and new developments at the journal, including broadening its remit to include the pharmacology underpinning successful therapeutics.
 
The journal will from April 2013 feature highlights of EACPT scientfic and other activities and provide information on future EACPT congresses, summer schools and other events. The journal will also publish peer-reviewed original papers and reviews arising from EACPT conferences.

Editor-in-Chief of Clinical Therapeutics Dr. Richard Shader welcomed the agreement reached with European Association of Clinical Pharmacology and Therapeutics (EACPT) to adopt Clinical Therapeutics as its Official Journal. 

He said “This interaction is timely both in view of the increasing need to meet international therapeutic challenges and the renewed editorial calendar to broaden the journal's scope to include the pharmacology underpinning successful therapeutics”.
See more about the new affiliation between EACPT and Clinical Therapeutics

Register for the 11th EACPT Congress in Geneva 28-31 August 2013

More on the Geneva EACPT Congress

Update on 28-31 August 2013 EACPT Congress in Geneva

-->

The abstract deadline for the next biennial EACPT Congress is only 6 weeks away: 8th April 2013.
See the EACPT Congress blog for summaries on many of the symposia to be held during the Congress: from new therapeutic biomarkers, to new biomarker and treatment targets (cancer, eye disease, predictive pharmacogenetics, inborn errors of metabolism, therapeutic drug monitoring ...), and how to improve safety in prescribing ...

The Congress will be held at the International Congress Centre of Geneva from 28 to 31 August 2013. 

-->
Over 900 participants are expected to attend including health professionals, scientists, policy makers, biotechnology and pharmaceutical professionals and others with an interest in basic and clinical pharmacology, pharmacotherapy, drug discovery and development, regulatory affairs and related areas.

Abstract submission

Registration

2013 EACPT Geneva Congress website.

Strategy development for the EACPT

EC members from UK, Sweden, Croatia and Italy

The European Association for Clinical Pharmacology and Therapeutics provides expert advice for European policy makers and medicines agencies, and organises congresses and workshops providing key information on the latest advances in research, education and policy on drug development and on the efficacy and safety of new and established medicines and their management. The EACPT  provides important additional support for its members, including representation and advocacy, training, and other aspects of development of the specialty.

EC members from France, Holland, Denmark, Finland and Germany

The international landscape for learned medical societies is evolving rapidly as a result of several key factors, including the impact of advances in molecular technology on drug discovery and development, changes in populations demographics, emergence of new therapeutic challenges,  the current global economic climate, and the effects of new e-technologies on ways of working and interacting for health and industry professionals, researchers and other interested in clinical sciences.

EC members from Holland, Spain, Germany & Hungary

The EACPT Executive Committee is in the process of conducting one of its regular strategy reviews, including evaluation of opportunities for the Assocation and its communities arising from the above developments. Results and actions arising from the strategy review will be discussed at the next biennial EACPT Congress to be held in Geneva 28-31 August 2013.

More on the EACPT Geneva 2013 Congress.

More on the 2013 EACPT Geneva Congress

The European Association for Clinical Pharmacology and Therapeutics 11th biennial Congress will be held at the International Congress Centre of Geneva (CICG) from 28 to 31 August 2013.

Cathedral and Lake Geneva fountain

Registration will open 10^th October 2012. Abstract submissions will also open 10^thOctober 2012 and will close 8^th February 2013. To receive updates on the congress before registering, you can submit your email address to the congress organisers.

Over 900 participants are expected to attend including health professionals, scientists, policy makers, biotechnology and pharmaceutical professionals and others with an interest in basic and clinical pharmacology, pharmacotherapy, drug discovery and development, regulatory affairs and related areas.

More information on the aims and key themes, and to contact the organisers, see:

2013 EACPT Congress updates 

Congress Website: http://www.eacpt2013.org

Secretariat email: eacptreg@mci-group.com

Update from Geneva

The latest meeting of the EACPT Executive has just finished in Geneva in advance of the next major EACPT biennial congress, which is to be held in this lakeside Swiss city in the summer of 2013.

Here are three important updates about the EACPT's scientific and educational programmes:

The next EACPT summer school will be held on 23rd to 25th August 2012 in Amsterdam, with an excellent range of topics for delegates interested in education in key principles relevant to clinical pharmacology. See the website for further information.

At the next European Pharmacology Congress in Granada  July 17th - 20th, 2012,  EACPT Vice-President Professor Tabassome Simon from Paris will give the keynote EACPT lecture on the application of pharmacogenetic testing to cardiovascular therapeutics.

Cathedral and Lake Geneva fountain (jet d'eau)

The EACPT is developing the programme for its next biennial congress, to be held in beautiful Geneva, 28th - 31st August in 2013. Key themes at the congress will range from bedside pharmacology for special patient groups to pharmacology & toxicology, and pharmacology and society. Specific topics will include advances in personalised diagnostics to improve the safety and effectiveness of medicines, updates on new biological approaches to ocular disease, therapeutics of cardiovascular, cancer and inflammatory disease, clinical trial design and regulation, and drug safety and toxicology.